Wuhan Hiteck Biological Pharma Co.,Ltd

SZSE:300683 Stock Report

Market Cap: CN¥3.2b

Wuhan Hiteck Biological PharmaLtd Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Ya Chen

Chief executive officer

CN¥989.2k

Total compensation

CEO salary percentagen/a
CEO tenure12yrs
CEO ownership8.4%
Management average tenureno data
Board average tenure5yrs

Recent management updates

Recent updates

Wuhan Hiteck Biological Pharma Co.,Ltd's (SZSE:300683) Shareholders Might Be Looking For Exit

Oct 02
Wuhan Hiteck Biological Pharma Co.,Ltd's (SZSE:300683) Shareholders Might Be Looking For Exit

There's No Escaping Wuhan Hiteck Biological Pharma Co.,Ltd's (SZSE:300683) Muted Revenues Despite A 28% Share Price Rise

Mar 08
There's No Escaping Wuhan Hiteck Biological Pharma Co.,Ltd's (SZSE:300683) Muted Revenues Despite A 28% Share Price Rise

CEO

Ya Chen (52 yo)

12yrs

Tenure

CN¥989,200

Compensation

Mr. Ya Chen serves as General Manager at Wuhan Hiteck Biological Pharma Co., Ltd. Mr. Chen serves as the General Manager of Yiyuan Tang Health Science and Technology Co., Ltd. He served as Deputy General M...

Board Members

NamePositionTenureCompensationOwnership
Ya Chen
Chairman of the Board & GM12yrsCN¥989.20k8.44%
CN¥ 269.0m
Han Zhen Xia
CFO & Director24.9yrsCN¥740.30kno data
Huang Chen
Deputy GM10.5yrsCN¥765.80kno data
Jia Feng Zhu
Director9.3yrsno datano data
Hua Dong Tang
Supervisor12yrsno datano data
Jie Yan
Director6yrsCN¥2.68m0.55%
CN¥ 17.6m
Mingdong Ran
Independent Director3.9yrsCN¥63.20kno data
Tao Yang
Non-Independent Director3yrsCN¥424.20kno data
Tao Wang
Independent Director3yrsCN¥63.20kno data
Haibing Zhou
Independent Director1.6yrsCN¥63.20kno data
Manqi Zhao
Chairman of the Supervisory Board1.6yrsno datano data
Zongfu mao
Independent Directorno datano datano data

5.0yrs

Average Tenure

54yo

Average Age

Experienced Board: 300683's board of directors are considered experienced (5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 08:34
End of Day Share Price 2024/12/25 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Wuhan Hiteck Biological Pharma Co.,Ltd is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jiaxi XuIndustrial Securities Co. Ltd.